At 6:55 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading highe ...

Group 1 - InMed Pharmaceuticals held its 2025 Annual General Meeting of Shareholders, chaired by CEO Eric Adams [1][2] - The meeting included a sworn declaration confirming that all materials were mailed to security holders as of October 22, 2025 [3]

InMed Provides Update on BayMedica Commercial BusinessDecember 12, 2025 5:31 PM EST | Source: InMed PharmaceuticalsVancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement. Recently, H.R. 5371, the "Continuing Appropriations, Agric ...

InMed Pharmaceuticals Conference Call Summary Company Overview - **Company Name**: InMed Pharmaceuticals (NasdaqCM: INM) - **Industry**: Pharmaceutical drug development - **Focus**: Proprietary small molecule drug candidates targeting CB1 and CB2 receptors [2][3] Key Drug Development Programs 1. **INM-901 for Alzheimer's Disease** - Target: Alzheimer's disease affecting up to 7.2 million Americans [5] - Preclinical data shows: - Statistically significant reduction in neuroinflammation [6] - Improvement in neuron growth and cognitive functions [7] - Ability to cross the blood-brain barrier [6] - Multiple mechanisms of action including neuroprotection and reduction of amyloid beta [8][10] - Long-term studies indicate improved behavior and cognition in animal models [11] 2. **INM-089 for Dry Age-Related Macular Degeneration (AMD)** - Target: Dry AMD affecting approximately 19.8 million Americans [16] - Mechanism: Preserves retinal function and heals damaged photoreceptor cells [17][18] - Delivery method: Injection into the eye [18] 3. **INM-755 for Epidermolysis Bullosa (EB)** - Focus: Cannabinol cream for chronic itch in EB patients [19] - Phase two clinical trial showed 66% of patients experienced clinically meaningful improvement in chronic itch [20] Financial Overview - **Cash Position**: $9.3 million as of September 30, providing approximately one year of runway [25] - **Market Capitalization**: Approximately $5.6 million [25] - **Shares Outstanding**: 4.2 million, fully diluted 6.7 million [25] Strategic Initiatives - Seeking partnerships for funding phase three trials, particularly for INM-755 [21] - Continuing to explore strategic partnerships to expedite drug development [22][23] - Focus on advancing INM-901 and INM-089 towards IND filings [26] Future Catalysts - Identifying strategic partners for drug development [30] - Presenting positive data at scientific conferences to attract interest [31] - Continued progress in preclinical studies for both INM-901 and INM-089 [32] Additional Insights - The company emphasizes the importance of addressing neuroinflammation in Alzheimer's and other diseases [12][28] - The leadership team is experienced in drug development, which is seen as a key strength [3][24] - The company maintains a clean balance sheet with no debt, allowing for focused investment in R&D [25]

Core Insights - InMed Pharmaceuticals Inc. shares experienced a significant increase of 21.98% in after-hours trading, reaching a price of $1.50 after closing at $1.23, which was a decline of 15.75% during the regular session [1]. Group 1: Study Milestones - The company announced the successful completion of pharmacokinetic studies in large animal models for its Alzheimer's disease candidate INM-901, marking the first preclinical study to administer the oral formulation in large animals [2]. - The studies demonstrated strong bioavailability in in vivo models over a seven-day period, achieving therapeutic systemic exposure levels for INM-901 [3]. Group 2: Regulatory Path Forward - InMed has completed additional chemistry, manufacturing, and controls development to scale production for Investigational New Drug-enabling studies. The company plans to conduct dose-ranging studies, a pre-IND meeting with the FDA, and Good Laboratory Practice-enabling studies to support its IND submission [4]. Group 3: Financial Position and Stock Performance - As of September 30, the company reported $9.3 million in cash, sufficient to fund operations into the fourth quarter of 2026. However, InMed's stock has declined by 74.38% year-to-date, trading within a 52-week range of $1.23 to $8.27, with a market capitalization of $3.45 million [5].

Core Insights - InMed Pharmaceuticals has successfully completed pharmacokinetic studies in large animal models for its Alzheimer's disease candidate INM-901, marking a significant step towards human clinical trials [1][2][3] Pharmacokinetic Study Results - The oral formulation of INM-901 demonstrated robust bioavailability over a seven-day dosing period, achieving therapeutic levels of systemic exposure, which supports its potential use in treating neurodegenerative disorders like Alzheimer's disease [3][4] - Neurological assessments showed no adverse neural or behavioral effects, reinforcing the compound's favorable safety profile [4][6] Development and Regulatory Preparation - InMed has advanced its chemistry, manufacturing, and controls (CMC) development to scale up the manufacturing process of INM-901 in preparation for Investigational New Drug (IND)-enabling studies and regulatory interactions with the FDA [5][10] - The company is preparing for a pre-IND meeting with the FDA and conducting dose-ranging studies in two species to support IND submission [9][10] Company Overview - InMed Pharmaceuticals focuses on developing proprietary small-molecule drug candidates targeting CB1/CB2 receptors, with a pipeline that includes programs for Alzheimer's, ocular, and dermatological indications [11]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Core Viewpoint - InMed Pharmaceuticals reported its financial results for the first quarter of fiscal year 2026, highlighting advancements in its lead program INM-901 for Alzheimer's disease and a solid financial position with $9.3 million in cash [1][3][11]. Financial Performance - The company generated revenues of $1.1 million for the three months ending September 30, 2025, down 11% from $1.3 million in the same period last year, primarily due to pricing adjustments [7][8]. - Research and development expenses decreased to $0.6 million from $0.7 million year-over-year, attributed to reduced spending on external contractors and compensation [9]. - General and administrative expenses remained stable at $1.5 million for both periods [10]. - The net loss for the period was $1.7 million, compared to a loss of $1.7 million in the previous year, with a net loss per share of $0.44 [13]. Business Update - INM-901 is advancing as a potential treatment for Alzheimer's disease, with ongoing IND-enabling activities and plans for a pre-IND meeting with the FDA [3][5]. - The company presented findings on INM-901 at the 2025 Alzheimer's Association International Conference, showcasing its therapeutic potential [4]. - INM-089 is under investigation for treating dry age-related macular degeneration, with preclinical studies showing significant improvements [6]. Cash Position - As of September 30, 2025, InMed had cash and cash equivalents of $9.3 million, down from $11.1 million at the end of June 2025, but expected to be sufficient to fund operations into the fourth quarter of calendar year 2026 [11].

Financial Performance - Sales for the three months ended September 30, 2025, were $1,120,121, a decrease of 11.4% compared to $1,264,638 for the same period in 2024[14]. - Gross profit for the quarter was $403,159, down from $493,413 in the prior year, indicating a decline of approximately 18.3%[14]. - The net loss for the period was $1,726,899, compared to a net loss of $1,677,868 in the prior year, reflecting an increase in loss of approximately 2.9%[14]. - For the three months ended September 30, 2025, InMed Pharmaceuticals reported a net loss of $1,726,899, compared to a net loss of $1,677,868 for the same period in 2024, indicating a year-over-year increase in losses of approximately 2.9%[18]. - Total cash used in operating activities for the three months ended September 30, 2025, was $1,607,616, a decrease of 12% compared to $1,826,810 for the same period in 2024[18]. - The company recognized total expenses from share-based payment transactions of $20,205 for the three months ended September 30, 2025, compared to $28,964 for the same period in 2024[76]. Assets and Liabilities - Total current assets decreased to $10,799,967 as of September 30, 2025, down from $12,867,279 as of June 30, 2025, representing a decline of approximately 16%[13]. - Cash and cash equivalents decreased to $9,331,077 as of September 30, 2025, down from $11,075,871 as of June 30, 2025, a reduction of about 15.7%[13]. - Total liabilities decreased to $1,770,462 as of September 30, 2025, from $2,145,545 as of June 30, 2025, a decline of approximately 17.5%[13]. - Shareholders' equity decreased to $11,590,623 as of September 30, 2025, down from $13,434,495 as of June 30, 2025, representing a decrease of about 13.7%[13]. - As of September 30, 2025, the Company reported total inventories of $890,807, a decrease from $961,173 as of June 30, 2025, with a write-down due to obsolescence amounting to $208,737[61]. - Accounts payable and accrued liabilities totaled $1,130,219 as of September 30, 2025, down from $1,404,283 as of June 30, 2025[64]. Funding and Financial Challenges - The company has an accumulated deficit of approximately $119 million as of September 30, 2025, reflecting ongoing financial challenges since inception[23]. - InMed expects its cash and cash equivalents will be sufficient to fund operations into the fourth quarter of calendar 2026, contingent on the timing of BayMedica revenues from bulk rare cannabinoids sales[24]. - The company has indicated substantial doubt about its ability to continue as a going concern within one year from the issuance of the financial statements, primarily due to recurring losses and negative cash flows[26]. - InMed is actively seeking additional funding through equity and debt financings, collaborations, and strategic transactions to support its operations[25]. Research and Development - Research and development expenses were $581,612 for the quarter, a decrease of 16.9% from $700,145 in the same quarter of 2024[14]. - The company continues to focus on optimizing proprietary manufacturing approaches and technologies to enhance production efficiency and product viability[8]. Shareholder Information - The company issued 602,000 common shares during the quarter, resulting in an increase in common shares outstanding to 2,604,186[16]. - The Company completed a Private Placement on June 26, 2025, raising approximately $5.0 million from the sale of 1,952,363 common shares at a price of $2.561 per share[67]. - As of September 30, 2025, the Company had 3,939,210 warrants outstanding with a weighted average exercise price of $48.43, down from 4,541,210 at the beginning of the period[73]. - The unrecognized compensation cost related to unvested options was $50,055, expected to be recognized over a weighted-average vesting period of approximately 1.13 years[77]. Segment Information - The company has two operating segments: Pharma, focused on drug development, and Commercial, focused on manufacturing technologies for cannabinoids[56]. - The company reported total sales of $1,120,121 in the Commercial segment for the three months ended September 30, 2025, a decrease from $1,264,638 in the same period of 2024[83]. - Total assets in the Pharma segment decreased from $13.7 million as of June 30, 2025, to $11.4 million as of September 30, 2025[82]. Intangible Assets and Amortization - The Company has intangible assets totaling $2,927,420 as of September 30, 2025, with accumulated amortization of $1,347,851, resulting in net intangible assets of $1,579,569[62]. - The Company expects to incur amortization expense of approximately $162,746 annually over the next five years for its intangible assets[63]. Lease Obligations - The company is committed to minimum lease payments totaling $668,267, with a present value of lease liabilities at $640,243 as of September 30, 2025[78]. - BayMedica is obligated to pay $1,295,759 over three years for a lease extension in South San Francisco, California[79].

Core Insights - InMed Pharmaceuticals has appointed Mr. John Bathery to its Board of Directors, effective immediately, to enhance its strategic capabilities in drug development [1][2][4] - Mr. Bathery has over 30 years of experience in the pharmaceutical industry, with a strong background in corporate development and strategic partnerships, having managed transactions exceeding $60 billion [2][3] - The company is advancing its INM-901 program for Alzheimer's disease and INM-089 program for Age-related Macular Degeneration towards clinical readiness [3] Company Overview - InMed Pharmaceuticals focuses on developing proprietary small molecule drug candidates targeting diseases with high unmet medical needs, including Alzheimer's and ocular conditions [5] - The company has a pipeline consisting of three separate programs aimed at treating Alzheimer's, ocular, and dermatological indications [5] Leadership Changes - Mr. Bryan Baldasare will not stand for re-election at the upcoming Annual General Meeting due to increasing professional obligations [3] - Andrew Hull, Chairman of the Board, expressed confidence in Mr. Bathery's expertise to drive the company's growth and strategic collaborations [4]